GlassScriptPhysician profile
Asim Guha Roy
NPI 1083659528
$5,669.59
in general payments reported to CMS, 2019-2025
35 companies · $790 in 2025
The $790 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $543 · 2021: $1,139 · 2022: $681 · 2023: $1,035 · 2024: $938 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661 · Travel and Lodging: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.43 |
| Travel and Lodging | $102.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $679.40 | 2020-2025 | Nayzilam, Briviact |
| Neurocrine Biosciences, INC. | $607.11 | 2022-2023 | Ingrezza |
| Acadia Pharmaceuticals INC | $515.94 | 2021-2023 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $450.68 | 2019-2021 | |
| Lilly USA, LLC | $359.20 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $315.74 | 2024-2025 | Farxiga |
| Cmp Pharma, INC. | $311.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $210.49 | 2022-2025 | Austedo Xr |
| Nevro Corp. | $201.61 | 2021-2024 | Senza |
| Janssen Pharmaceuticals, INC | $171.21 | 2019 | |
| Inspire Medical Systems, INC. | $156.05 | 2024-2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $153.72 | 2023-2025 | Rexulti |
| Edwards Lifesciences Corporation | $151.94 | 2019 | |
| Dexcom, INC. | $150.90 | 2023 | Dexcom G7 Gss (161) |
| Si-Bone, INC. | $143.73 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $126.35 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $124.91 | 2021 | |
| Horizon Therapeutics Plc | $124.48 | 2023 | Krystexxa |
| Amgen INC. | $122.09 | 2025 | Uplizna |
| Glaxosmithkline, LLC. | $114.60 | 2023 | Nucala |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.36 | 2023-2024 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $41.54 | 2023 | Gemtesa |
| Microtransponder, INC. | $34.22 | 2025 | |
| Merck Sharp & Dohme LLC | $29.72 | 2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $29.12 | 2022 | |
| Vanda Pharmaceuticals INC. | $26.96 | 2024 | Fanapt |
| Urovant Sciences INC | $24.73 | 2022 | |
| Averitas Pharma INC. | $24.09 | 2023 | Qutenza |
| Corcept Therapeutics | $23.43 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $19.57 | 2025 | Nexletol |
| Avanir Pharmaceuticals, INC. | $18.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.56 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.09 | 2024 | Keveyis |
| Cequr Corporation | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asim Guha Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.